EICHORCondition: Leukemia · Acute Leukemia · Acute Lymphoid Leukemia · Sponsor: UNC Lineberger Comprehensive Cancer Center
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Acute lymphoblastic leukemia (ALL) is the most common cancer in children and, along with lymphoblastic lymphoma, represents the most common group of childhood lymphoid malignancies. Survival rates have improved over the years, but many children still experience long-term side effects from treatment. These can include tiredness, weak muscles, pain, nerve problems, difficulty moving, and other physical challenges. Many children with ALL are also overweight at diagnosis, and weight gain often continues during treatment. As a result, about half of childhood leukemia survivors have a BMI at or above the 85th percentile. Treatment decisions are usually based on a child's symptoms and genetic risk factors. However, some risk factors such as physical activity can be modified. Exercise during treatment may help children feel better and may even improve survival. However, research on early symptom tracking and structured exercise during the first phase of chemotherapy is limited, uses different methods, and often does not include reliable patient-reported symptoms. Effective exercise programs for children with ALL and lymphoblastic lymphoma need to consider the child's age, treatment side effects, motivation, family support, and ways to encourage long-term behavior change. Because children spend little time in the hospital during the induction phase, a mix of in-person and virtual sessions supported by real-time Zoom instruction can make it possible to offer safe and supervised exerc…
This description comes directly from the study's public registry record.
Jessica Buddenbaum, MS · 919-966-4432 · jessica_buddenbaum@med.unc.edu
Juanita Cuffee · 919-216-0463 · cuffee@med.unc.edu
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria for children: All subjects must meet the following criteria: * Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. OR Written assent and parental/legal guardian consent. * Age \>= 6 and \< =21 years at the time of diagnosis. * Newly- diagnosed with one of the following diseases: B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma Exclusion Criteria for children: * Subjects must not be receiving any investigational or additional anti-cancer medicines during induction. * Significant concurrent disease, illness, or psychiatric disorder or social issue that would compromise subject safety or adherence to the protocol treatment or procedures, interfere with consent, study participation, follow-up, or interpretation of the study results. Optional caregiver participation: Inclusion Criteria :All caregivers must meet the following criteria * Written informed consent to participate in the caregiver interviews. * The caregiver must be a parent or legal guardian ≥ 18 years old, and their child must be \<18 years
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center | Chapel Hill, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07634653